Executive Summary: Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline and Expert Panel Report
Research article published in Chest (2021)
Abstract
BACKGROUND: This is the 2nd update to the 9th edition of these guidelines. We provide recommendations on 17 PICO (Population, Intervention, Comparator, Outcome) questions, four of which have not been addressed previously. METHODS: We generate strong and weak recommendations based on high-, moderate-, and low-certainty evidence, using GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) methodology. RESULTS: The panel generated 29 guidance statements, 13 of which are graded as strong recommendations, covering aspects of antithrombotic management of VTE from initial management through secondary prevention and risk reduction of postthrombotic syndrome. Four new guidance statements have been added that did not appear in the 9th edition (2012) or 1st update (2016). Eight statements have been substantially modified from the 1st update. CONCLUSION: New evidence has emerged since 2016 that further informs the standard of care for patients with VTE. Substantial uncertainty remains regarding important management questions, particularly in limited disease and special patient populations.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Resumen
Peer-reviewed clinical and outcomes research relevant to medicinal leech therapy and its biology. Indexed in PubMed and verified against the NCBI record.
Por qué esto importa para la hirudoterapia
Este resumen ejecutivo de la segunda actualización de la guía CHEST de la 9.ª edición utilizó la metodología GRADE para abordar 17 preguntas PICO y emitió 29 declaraciones de orientación (13 recomendaciones fuertes) que abarcan el manejo inicial, la prevención secundaria y la reducción del síndrome postrombótico en VTE. Es relevante para ASH como la referencia autorizada del estándar de atención que enmarca cómo se trata realmente la tromboembolia venosa, el contexto clínico frente al cual se posiciona la justificación antitrombótica para el secretoma de la sanguijuela medicinal. Este es un documento de guía/panel de expertos que sintetiza la evidencia existente en lugar de generar datos nuevos, no hace mención de la hirudoterapia ni de los agentes derivados de sanguijuelas, y reconoce por sí mismo una incertidumbre residual sustancial en la enfermedad limitada y las poblaciones especiales.
Citación
Executive Summary: Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline and Expert Panel Report.
Stevens et al. · Chest, 2021
Contexto clínico relacionado
Explore cómo esta investigación se conecta con la práctica clínica
Añadido a la biblioteca ASH: May 28, 2026 · Última actualización del sitio: June 18, 2026